Geographical distribution of host's specific SARS-CoV-2 mutations in the early phase of the COVID-19 pandemic.
Mutation
NSP6
Nucleotide sequences
ORF-8
SARS-CoV-2
Journal
Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761
Informations de publication
Date de publication:
30 Jan 2023
30 Jan 2023
Historique:
received:
04
06
2022
revised:
24
10
2022
accepted:
25
10
2022
pubmed:
8
11
2022
medline:
30
11
2022
entrez:
7
11
2022
Statut:
ppublish
Résumé
To assess, if the SARS-CoV-2 mutate in a similar pattern globally or has a specific pattern in any given population. We report, the insertion of TTT at 11085, which adds an extra amino acid, F to the NSP6 at amino acid position 38. The highest occurrence of TTT insertion at 11,085 position was found in UK derived samples (65.97%). The second and third highest occurrence of the mutation were found in Australia (8.3%) and USA (4.16%) derived samples, respectively. Another important discovery of this study is the C27945T mutation, which translates into the termination of ORF-8 after 17 amino acids, reveals that the SARS-CoV-2 can replicate without the intact ORF-8 protein. We found that the 97% of C27945T mutation of global occurrence, occurred in Europe and the USA derived samples. Two of the reported mutations (11085TTT insertion and C27945T nonsense), which seemed to reduce Type I interferon response are linked to specific geographical locations of the host and implicate region-specific mutations in the virus. The findings of this study signify that SARS-CoV-2 has the potential to adapt differently to different populations.
Identifiants
pubmed: 36343703
pii: S0378-1119(22)00840-X
doi: 10.1016/j.gene.2022.147020
pmc: PMC9635256
pii:
doi:
Substances chimiques
Amino Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147020Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Infect Genet Evol. 2020 Jul;81:104260
pubmed: 32092483
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Infect Genet Evol. 2020 Nov;85:104525
pubmed: 32890763
J Virol. 2012 May;86(9):4906-20
pubmed: 22345473
J Med Virol. 2020 Jun;92(6):667-674
pubmed: 32167180
Cell Rep. 2020 Oct 6;33(1):108234
pubmed: 32979938
Natl Sci Rev. 2020 Jun;7(6):1012-1023
pubmed: 34676127
Nature. 2020 Nov;587(7834):374-376
pubmed: 33139913
Vaccines (Basel). 2022 Aug 19;10(8):
pubmed: 36016239
Virus Res. 2020 Sep;286:198074
pubmed: 32589897
Osong Public Health Res Perspect. 2020 Jun;11(3):101-111
pubmed: 32528815
J Hum Genet. 2020 Dec;65(12):1075-1082
pubmed: 32699345
Biochem Biophys Res Commun. 2021 Jan 29;538:116-124
pubmed: 33685621
Genes (Basel). 2020 Jul 07;11(7):
pubmed: 32646049
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
J Infect. 2020 Jul;81(1):e24-e27
pubmed: 32283146
mBio. 2013 Aug 13;4(4):
pubmed: 23943763
mSphere. 2020 Jun 24;5(3):
pubmed: 32581081
Virus Res. 2006 Apr;117(1):17-37
pubmed: 16503362
Euro Surveill. 2020 Apr;25(13):
pubmed: 32265007
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Nature. 1996 Aug 22;382(6593):722-5
pubmed: 8751444
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
J Virol. 2018 Jun 29;92(14):
pubmed: 29720522
J Transl Med. 2020 Apr 22;18(1):179
pubmed: 32321524
Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):
pubmed: 33361333
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508